Riociguat for pulmonary hypertension

References

• Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30(20):2493-537
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173(9):1023-30
   PubMed Web of Science ®Google Scholar
• Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012;186(8):790-6
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Murphy NF, Mcmurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30(1):104-9
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350(22):2257-64
   PubMed Web of Science ®Google Scholar
• Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;33(2):325-31
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Gibbs JSR, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;33(2):332-8
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124(18):1973-81
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Gibbs JSR, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008;177(10):1122-7
   PubMed Web of Science ®Google Scholar
• Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93(9):1137-46
   PubMed Web of Science ®Google Scholar
• Bonderman D, Martischnig AM, Moertl D, Lang IM. Pulmonary hypertension in chronic heart failure. Int J Clin Pract 2009;161(Suppl):4-10
   Google Scholar
• Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008;31(6):1357-67
   PubMed Web of Science ®Google Scholar
• Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127(5):1531-6
   PubMed Web of Science ®Google Scholar
• D’alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115(5):343-9
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012;142(2):448-56
   PubMed Web of Science ®Google Scholar
• Jenkins DP, Madani M, Mayer E, et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2013;41(3):735-42
   PubMed Web of Science ®Google Scholar
• Simonneau G, Delcroix M, Lang I, et al. Long-term outcome patients with chronic thromboembolic pulmonary hypertension: Results of an international prospective registry comparing operated versus non-operated patients. Am J Respir Crit Care Med 2013;187_1(Meeting Abstracts):A5365
   Google Scholar
• Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007;99(8):1146-50
   PubMedGoogle Scholar
• Guignabert C, Dorfmuller P. Pathology and pathobiology of pulmonary hypertension. Semin Respir Crit Care Med 2013;34(5):551-9
   PubMed Web of Science ®Google Scholar
• International PPH Consortium. Lane KB, Machado RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26(1):81-4
   PubMedGoogle Scholar
• Austin ED, Loyd JE. Heritable forms of pulmonary arterial hypertension. Semin Respir Crit Care Med 2013;34(5):568-80
   PubMed Web of Science ®Google Scholar
• Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013;369(4):351-61
   PubMed Web of Science ®Google Scholar
• Cannon JE, Pepke-Zaba J. Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs? Semin Respir Crit Care Med 2013;34(5):620-6
   PubMed Web of Science ®Google Scholar
• Christman BW, Mcpherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327(2):70-5
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiéry J-L, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39(9):1496-502
   PubMed Web of Science ®Google Scholar
• Mclaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55(18):1915-22
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4
   PubMed Web of Science ®Google Scholar
• Barst RJ, Mcgoon M, Mclaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2119-25
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328(24):1732-9
   PubMed Web of Science ®Google Scholar
• Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-19
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369(9):809-18
   PubMed Web of Science ®Google Scholar
• Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5(9):755-68
   PubMed Web of Science ®Google Scholar
• Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894-903
   PubMed Web of Science ®Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, Voswinckel R, Gall H, et al. Riociguat for pulmonary hypertension. Fut Cardiol 2010;6(2):155-66
   PubMedGoogle Scholar
• Schermuly RT, Stasch J-P, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32(4):881-91
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297(6):L1013-32
   PubMed Web of Science ®Google Scholar
• Lang M, Kojonazarov B, Tian X, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One 2012;7(8):e43433
   PubMed Web of Science ®Google Scholar
• Abe K, Toba M, Alzoubi A, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121(25):2747-54
   PubMed Web of Science ®Google Scholar
• Frey R, Mück W, Unger S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008;48(8):926-34
   PubMed Web of Science ®Google Scholar
• Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33(4):785-92
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36(4):792-9
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369(4):330-40
   PubMed Web of Science ®Google Scholar
• Galie N, Neuser D, Muller K, et al. A placebo controlled, double-blind phase II interaction study to evaluate blood pressure following addition of riocigat to patients with symptomatic pulmonary arterial hypertension receiving sildenadil (PATENT Plus). Am J Respir Crit Care Med 2013;187_1(Meeting Abstracts):A3530
   Google Scholar
• Skoro-Sajer N, Hack N, Sadushi-Koliçi R, et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation 2009;119(2):298-305
   PubMedGoogle Scholar
• Suntharalingam J, Hughes RJ, Goldsmith K, et al. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Vascul Pharmacol 2007;46(6):449-55
   PubMed Web of Science ®Google Scholar
• Ulrich S, Fischler M, Speich R, et al. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 2006;130(3):841-6
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, D’armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369(4):319-29
   PubMed Web of Science ®Google Scholar
• Jaïs X, D’armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52(25):2127-34
   PubMed Web of Science ®Google Scholar
• Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134(2):229-36
   PubMed Web of Science ®Google Scholar
• Archer SL. Riociguat for pulmonary hypertension--a glass half full. N Engl J Med 2013;369(4):386-8
   PubMedGoogle Scholar
• Van Der Plas MN, Surie S, Reesink HJ, et al. Longitudinal follow-up of six-minute walk distance after pulmonary endarterectomy. Ann Thorac Surg 2011;91(4):1094-9
   PubMedGoogle Scholar
• Califf RM, Adams KF, Mckenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134(1):44-54
   PubMed Web of Science ®Google Scholar
• Kalra PR, Moon JCC, Coats AJS. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85(2-3):195-7
   PubMed Web of Science ®Google Scholar
• Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 2010;7(11):648-59
   PubMed Web of Science ®Google Scholar
• Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000;102(14):1718-23
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail 2012;14(1):82-90
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011;4(1):8-17
   PubMed Web of Science ®Google Scholar
• Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007;115(1):59-66
   PubMed Web of Science ®Google Scholar
• Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309(12):1268-77
   PubMed Web of Science ®Google Scholar
• Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013;128(5):502-11
   PubMed Web of Science ®Google Scholar
• Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute haemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE-1): a randomised, double-blind, placebo-controlled, single dose study. Eur Heart J 2013;34:suppl 1
   PubMedGoogle Scholar
• Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131(3):897-9
   PubMedGoogle Scholar
• Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360(9337):895-900
   PubMed Web of Science ®Google Scholar
• Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160(2):600-7
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013;41(4):853-60
   PubMed Web of Science ®Google Scholar
• Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363(7):620-8
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Staechler G, Gruenig E, et al. The effect of the soluble guanylate cyclase stimulator riociguat on haemodynamics in patients with pulmonary hypertension due to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:A6127
   Google Scholar
• Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32(5):1371-85
   PubMed Web of Science ®Google Scholar
• Rubin L, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): 1-year results from the PATENT-2 long term extension study. Chest 2013;144(4 Meeting Abstracts):1042A
   Google Scholar
• Simonneau G, D’armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1-year results from the CHEST-2 long-term extension study. Chest 2013;144(4 Meeting Abstracts):1023A
   Google Scholar
• Frey R, Mück W, Kirschbaum N, et al. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol 2011;51(7):1051-60
   PubMed Web of Science ®Google Scholar
• Briefing Document for Cardiovascular and Renal Drugs Advisory Committee. Available from: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm363543.pdf [Last accessed 28 October 2013]
   Google Scholar
• Galie N, Simonneau G. The Fifth World Symposium on Pulmonary Hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D1-3
   PubMed Web of Science ®Google Scholar
• Ghofrani HA. The future role of soluble guanylate cyclase stimulators in clinical practice. Presented at: 2013 European Respiratory Society Meeting; 2013
   Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351(14):1425-36
   PubMed Web of Science ®Google Scholar